苑东生物：注射用YLSH003启动Ⅰ/Ⅱ期临床试验并完成首例受试者入组

Core Viewpoint - Yuan Dong Biotech (688513) announced that its wholly-owned subsidiary, Shanghai Youluo, has initiated Phase I/II clinical trials for its self-developed Class I biological drug, YLSH003, targeting advanced solid tumors, with the first subject successfully enrolled for treatment recently [1] Group 1 - The company is advancing its clinical research with YLSH003, which is a significant step in its drug development pipeline [1] - The initiation of clinical trials indicates the company's commitment to addressing unmet medical needs in oncology [1] - The successful enrollment of the first subject marks a critical milestone in the development process of YLSH003 [1]